Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interventional Cardiology KOL Joins Abiomed

This article was originally published in Clinica

Executive Summary

Percutaneous heart pump maker Abiomed has appointed Dr Seth Bilazarian Vice-President of Interventional Cardiology Programs. Bilazarian has over 20 years’ experience practicing interventional cardiology in the cath lab with expertise in hemodynamic support; he has also served as physician advisor to the cardiac device panel of the US FDA. His role at Abiomed includes collaborating with other physicians to develop best practices for use of the company’s Impella platform in Protected PCI and helping the company develop new devices within the platform. Abiomed is currently seeking expanded indications for Impella to include patients suffering cardiogenic shock following acute myocardial infarction or cardiac surgery.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT102912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel